105 results about "Bephenium Compounds" patented technology

In the method of the present invention, xylylenediamine is produced by a two-stage hydrogenation of a dicyanobenzene compound. In a first stage (a), the hydrogenation is performed until a conversion of nitrile groups reaches 90 mol % or higher and less than 99.9 mol %. In a second stage (b), the hydrogenation is further continued at temperatures 10° C. or more higher than in the step (a) until the conversion of nitrile groups reaches a level which is higher than that attained in the step (a) and equal to 99.5 mol % or more. In the present invention, a highly pure xylylenediamine containing a minimized amount of cyanobenzylamine is efficiently produced in a simple manner without needing a specific purification, and also without deteriorating the use efficiency of the catalyst while reducing the amount of the dicyanobenzene compound remaining not reacted and the generation of the intermediate cyanobenzylamine.

The present invention provides a medicament comprising a benzene compound useful as an insulin sensitizer, a salt thereof or a hydrate of them and a derivative of them as the active ingredient. Specifically, it provides a benzene compound represented by the following formula, a salt thereof or a hydrate of them. In the formula, X represents 1) a C6-10 aryl group which may have one or more substituents or 2) a 5- to 10-membered heteroaryl group which may have one or more substituents; Y represents a group represented by the formula: (in the above formulae, R<y1>, R<y2 >and R<y3 >are the same as or different from one another and each represents a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, or a C3-7 cycloalkyl group) etc.; Z represents a group represented by the formula: (in the formula, m represents an integer of 0 to 2; R<z1, R><z2>, R<z3 >and R<z4 >are the same as or different from one another and each represents a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C3-7 cycloalkyl group, a halogenated C1-6 alkyl group, a halogenated C1-6 alkoxy group etc.); and R<1>, R<2>, R<3 >and R<4 >are the same as or different from one another and each represents a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C3-7 cycloalkyl group etc.

The present invention refers to a crystalline 2-fluoro-3-nitrotoluene compound of formula (I), and a process for the preparation thereof. Furthermore, the present invention relates to a process for the synthesis of a compound of formula (II) or salts thereof by means of the crystalline 2-fluoro-3-nitrotoluene.

An intermediate of a heteroacene compound is represented by Chemical Formula 1.

The compounds represented by the formula (I) are produced by reacting benzene compound of the formula (IV) or (V) with alkenylidene diacetate of the formula (VI) in the presence of a catalyst comprising one or more members selected from (a) halogenated boron compounds, (b) triflate compounds of Group 11 elements, (c) halogenated compounds of Group 12 elements, and (d) triflate and halogenated compounds of tin and atomic numbers 58 and 66 to 71 elements. R<1>, R<2> = H or C1 - C10 alkyl group A = Substituted phenyl group corresponding to a compound of formula (IV) or (V), R<3>, R<4> = H or C1 - C4 alkyl group, m = 0 or 1 - 4, n = 1 to 5, k = 1 or 2.

A method of producing honokiol and analogues thereof, and novel intermediates prepared by virtue thereof are disclosed herein. A pharmaceutical composition for treating Parkinson's disease, which contains honokiol and/or the analogues thereof, is also disclosed herein.

The invention discloses a flexible light-transmitting metamaterial composite film and method for detecting nitrite. A single layer of metal nanoparticle array is formed on a soft light-transmitting substrate as a metamaterial layer, and a p-aminothiophenol self-assembled monomolecular film covers the single layer of metal nanoparticle array as a nitrite sensitive film; under the excitation of visible/near infrared light, surface plasmon resonance is generated on the metamaterial layer; p-aminothiophenol in the nitrite sensitive film is induced to be converted into an azobenzene compound underthe synergistic action of surface ions of the metamaterial layer and sub-salt nitrate ions; since the molecules of the azobenzene compound and the molecules of the p-aminothiophenol have a significantdifference in the aspect of Raman spectrum, the reaction is directly monitored by using the Raman spectrum, and the specific recognition and detection of nitrite ions are indirectly realized. The method utilizes the special optical properties possessed by the metamaterial and combines the surface selectively of sub-salt nitric acid to catalyze aniline so as to generate the azobenzene, thereby realizing the rapid detection of nitrite.

The invention discloses a preparation method of a monatomic metal-nitrogen doped carbon aerogel electrocatalyst, and aims to meet the urgent demand of the field of electrocatalysis on large-scale preparation of a low-cost and high-activity monatomic electrocatalyst. According to the technical scheme, the preparation method comprises the following steps: firstly, preparing an organic solution or sol A from aldehyde organic matters containing aldehyde groups, polyhydroxy benzene compounds or polyamino benzene compounds; preparing a metal complex solution or sol B from an inorganic metal salt and an organic matter which can generate a complex with the inorganic metal salt or can catalyze metal salt ions to form metal cation sol; mixing and heating A and B to obtain metal-doped organic matter gel C; removing liquid in the C to obtain metal-doped organic matter aerogel; and cracking the metal doped organic matter aerogel to obtain the monatomic metal-nitrogen doped carbon aerogel electrocatalyst. The acid pickling step is avoided, active sites are generated in one step in situ in the cracking process, the method is simple and low in cost, and the electrocatalyst prepared through the method is very high in catalytic activity.

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

The embodiment of the invention provides a quantum dot ligand structure, a luminescent device, a preparation method and a display device. The quantum dot ligand structure is an azobenzene compound; each benzene ring of the azobenzene compound has at least one group, and coordinate bonds can be formed between the groups and quantum dots. According to the quantum dot ligand structure provided by the embodiment of the invention, the quantum dot ligand structure is the azobenzene compound, each benzene ring of the azobenzene compound has at least one group, the groups on the benzene rings of the azobenzene compound can be connected with quantum dots through the coordinate bonds, the quantum dot ligand structure can be connected with the quantum dots through the coordinate bonds, and therefore, a net-shaped or chain-shaped structure can be formed easily, the problem that surface atom coordination of the quantum dots is insufficient is avoided, unsaturated bonds are reduced, and surface defects of the quantum dots are reduced; the azobenzene compound has the carrier transmission characteristic, the transmission rate of carriers among the quantum dots is increased, the luminous efficiency of the quantum dots is improved, and the service life of the luminescent device is prolonged.

The invention discloses a method for preparing an alpha-aryl carbonyl compound, which comprises the following steps: activating an R1 substituted iodobenzene diacetate compound by Lewis acid, and then reacting with an R2 substituted oxazoline compound in the presence of alkali to obtain the alpha-aryl carbonyl compound, wherein R1 is selected from H, one or more alkyl groups, one or more halogenated alkyl groups, alkoxycarbonyl, halogen or multi-substitution formed by the combination of the above atoms, and R2 is selected from H, alkyl and substituted alkyl, wherein a substituent group is selected from cycloalkyl, halogen, alkoxy, heterocycloalkyl, substituted heterocycloalkyl, aryl, cyano, aryloxy and carbonyl. The method has the advantages of mild reaction conditions, easy product separation and simple operation.

The present invention relates to radiolabelled substitute benzene compounds for diagnostic imaging. The present invention provides methods for preparation of such compounds, in particular, preparation of novel compounds which serve as precursors for <18>F-labeling, and the use of thus <18>F-labeled compounds for diagnostic imaging. Formula (A), wherein one of -Y1, -Y2, -Y3 Y4 and -Y5 is -A-B-D-P, wherein -A-B-D- is a bond or spacer, P is peptide, peptidomimetic, oligonucleotide or small molecule. K is LG-O or W, wherein: LG- is selected from the group comprising Formula (B), wherein T is H or Cl, Q is CH or N, K is absent or is C=O. W is radioactive or non-radioactive isotope of fluorine, more preferably <18>F.

The invention provides an NDI (naphthalene diisocyanate)-rylene compound formed by the reaction between a NDI tin compound and a rylene compound. The rylene compound can be a perylene compound, and the NDI-rylene compound can be used in an organic electronic device (including a field effect transistor).